Rivastigmine. A review of its use in Alzheimer's disease.

@article{Spencer1998RivastigmineAR,
  title={Rivastigmine. A review of its use in Alzheimer's disease.},
  author={Caroline M. Spencer and Stuart Noble},
  journal={Drugs & aging},
  year={1998},
  volume={13 5},
  pages={391-411}
}
UNLABELLED Rivastigmine (SDZ ENA 713) is a carbamylating, long-acting reversible and noncompetitive carbamate acetylcholinesterase inhibitor that is indicated as an oral treatment for patients with mild to moderately severe Alzheimer's disease. The drug has been evaluated for this use in 3 well designed, adequately powered, phase II/III, 26-week clinical trials that included a total of 1479 rivastigmine and 647 placebo recipients. Most of these patients had concomitant disorders that were being… CONTINUE READING
30 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…